The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer
Xinchao Zhao,Yawen Zheng,Yufeng Wang,Mingyan Zhang,Zhilin Dong,Yanan Liu,Meili Sun
DOI: https://doi.org/10.2147/ott.s484209
IF: 4
2024-11-21
OncoTargets and Therapy
Abstract:Xinchao Zhao, &ast Yawen Zheng, &ast Yufeng Wang, Mingyan Zhang, Zhilin Dong, Yanan Liu, Meili Sun Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Meili Sun, Email In non-small cell lung cancer (NSCLC), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in up to 30% of all cases, with the most prevalent mutations occurring in codons 12 and 13. The development of KRAS -targeted drugs like sotorasib and adagrasib has generated significant excitement in the clinical arena, offering new therapeutic options. Their potential for combination with other treatments broadens the scope for clinical exploration. Acquired resistance to KRAS exon 2 p.G12C inhibitors is a significant challenge, with several reported mechanisms. In this scenario, combination therapy strategies that include targeting Src Homology Region 2 Domain-Containing Phosphatase-2 (SHP2), Son of Sevenless Homolog 1 (SOS1), or downstream effectors of KRAS exon 2 p.G12C are showing promise in overcoming such resistance. However, the efficacy of immune checkpoint inhibitors in this context still requires comprehensive evaluation. The response to anti-Programmed Cell Death Protein 1/Programmed Cell Death Protein 1 Ligand (anti-PD-1/PD-L1) drugs in NSCLC may be significantly influenced by co-occurring mutations, underscoring the need for a personalized approach to treatment based on the specific genetic profile of each tumor. Keywords: targeted therapies, sotorasib, adagrasib, resistance Lung cancer remains the leading cause of cancer-related deaths globally, with nearly 1.8 million fatalities annually. Among these, NSCLC represents the majority, accounting for about 85% of all lung cancer diagnoses, with adenocarcinoma being the most prevalent histological subtype. In recent years, advancements in molecular profiling and the development of novel targeted therapies have significantly transformed the treatment landscape for NSCLC. Simultaneously, the rise of immune checkpoint inhibitors has broadened the spectrum of therapeutic strategies available for lung cancer. Notably, combination therapies that incorporate immune checkpoint inhibitors alongside targeted drugs have shown superior efficacy compared to monotherapy approaches. Previously, certain molecular alterations like KRAS mutations were deemed untreatable, but the advent of new targeted drugs has opened up promising treatment possibilities for these challenging cases. This shift marks a pivotal moment in the ongoing efforts to effectively treat and manage NSCLC. The KRAS protein, a small membrane-bound Guanosine Triphosphatase (GTPase), plays a critical role as a molecular switch regulating various cellular signaling functions. Its activity within the cell is determined by the balance between nucleotide hydrolysis and exchange, which governs the amount of active KRAS . In its GDP-bound form, KRAS remains in an "off" state. However, upon exposure to growth factors, KRAS transitions to the "on" state through the exchange of GDP for GTP. This activation process is facilitated by guanine nucleotide exchange factors (GEFs) like SOS1 and SOS2. Once activated, KRAS triggers downstream effector pathways, notably the Mitogen-Activated Protein Kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, which are essential for cell proliferation and survival. The return of KRAS to the "off" state occurs when GTP is hydrolyzed back to GDP, a reaction catalyzed by GTPase-activating proteins (GAPs) such as neurofibromatosis type 1 (NF1). 1 This dynamic cycle of activation and deactivation is crucial for the precise regulation of cellular processes influenced by KRAS . This article comprehensively explores various aspects of KRAS mutations in NSCLC, with a focus on targeted therapies and combination treatment strategies for KRAS -mutant NSCLC. KRAS mutations represent the most prevalent carcinogenic driver in NSCLC, with their incidence varying significantly based on the lung cancer's pathological type, ethnicity, smoking history, and gender. In Caucasian populations, KRAS mutations are found in approximately 30% of lung adenocarcinomas, whereas they occur less frequently in lung squamous cell carcinoma, with an incidence ranging from 1.6% to 7.1%. 2 In large cell lung cancer and adenosquamous carcinoma, the incidence rates are 12.8% and 10%, respectively. Beyond ethnic differences, KRAS mutations tend to be more common among women and individuals with a history of smoking. 3 A strong correlation has been established be -Abstract Truncated-
oncology,biotechnology & applied microbiology